2-amino-4-chloro-8-methoxyquinazoline | 124309-87-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 2-amino-4-chloro-8-methoxyquinazoline
• 英文别名: 4-chloro-8-methoxyquinazolin-2-amine
• CAS: 124309-87-1
• 化学式: C₉H₈ClN₃O
• 分子量: 209.635
• InChiKey: JTPWONLDCZSTAX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  14
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.11
• 拓扑面积：
  61
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-amino-4-chloro-8-methoxyquinazoline 生成 2-amino-4-(N-methylphenylamino)-8-methoxyquinazoline hydrochloride
  参考文献：
  名称：

  Substituted quinazoline derivatives for use in gastrointestinal diseases

  摘要：

  2,4-二氨基喹唑啉化合物是H.sup.+ K.sup.+ ATP酶的抑制剂，对基于胃酸分泌过多的胃病的治疗有用。该发明的化合物是2-[2-甲基-4-氟苯基)氨基]-4-(N-甲基苯胺基)喹唑啉。

  公开号：

  US05064833A1
• 作为产物：
  描述：

  2-amino-8-methoxyquinazolin-4-ol 在 N,N-二甲基苯胺 、 三氯氧磷 作用下， 反应 0.75h， 以74%的产率得到2-amino-4-chloro-8-methoxyquinazoline
  参考文献：
  名称：

  Reversible Inhibitors of the Gastric (H+/K+)-ATPase. 5. Substituted 2,4-Diaminoquinazolines and Thienopyrimidines

  摘要：

  Quinazolines bearing a secondary 4-(arylamino) substituent demonstrate an SAR for inhibition of the gastric (H+/K+)-ATPase different from the previously described 3-acylquinolines, suggesting that, although these compounds are also K+-competitive, they probably bind to the enzyme in a different orientation. Compounds bearing a tertiary 4-(arylamino) substituent, however, in particular 4-(N-methylarylamino), appear to possess an SAR quite similar to the 3-acylquinolines. We show that this arises from the effect of the N-methylation, which is to orientate the 4-(arylamino) substituent syn to C-5, analogous to the 3-acylquinolines. Compounds possessing both a 4-(N-methylarylamino) substituent and a 2-(arylamino) substituent proved to be very potent, K+-competitive inhibitors of K+-stimulated ATPase activity with K-i values down to 12 nM. Some compounds also proved to be effective inhibitors of stimulated acid secretion in both the rat and dog when dosed intravenously. However, although a number of these demonstrated activity after oral administration in the dog, the level and variability precluded further evaluation.

  DOI：

  10.1021/jm00014a027

文献信息

• HETEROBICYCLO-SUBSTITUTED [1,2,4]TRIAZOLO[1,5-C]QUINAZOLIN-5-AMINE COMPOUNDS WITH A2A ANTAGONIST PROPERTIES
  申请人：ALI Amjad

  公开号：US20150361098A1

  公开（公告）日：2015-12-17

  Disclosed are compounds of Formula G1 (structurally represented): where “RG3” “Rd1” to “Rd4”, “n”, “m”, “p”, “W”, “X”, “Y”, and “Z” are defined herein which compounds are antagonists of A2A receptor. Disclosed herein also are uses of the compounds described herein as antagonists of the A2a receptor in the potential treatment or prevention of neurological disorders and diseases in which A2A receptors are involved. Disclosed herein also are pharmaceutical compositions comprising these compounds and uses of these pharmaceutical compositions.

  本文披露了G1式化合物（结构式表示）：其中“RG3”、“Rd1”至“Rd4”、“n”、“m”、“p”、“W”、“X”、“Y”和“Z”在此定义，这些化合物是A2A受体的拮抗剂。本文还披露了所述化合物作为A2A受体拮抗剂在潜在的涉及A2A受体的神经系统疾病的治疗或预防中的用途。本文还披露了包含这些化合物的制药组合物和这些制药组合物的用途。
• Quinazoline-pyridine derivatives for the treatment of cancer-related disorders
  申请人：ARCUS BIOSCIENCES, INC.

  公开号：US11045472B2

  公开（公告）日：2021-06-29

  Compounds of Formula I that inhibit at least one of the A2A and A2B adenosine receptors, and compositions containing compounds of Formula I and methods for synthesizing compounds of Formula I, are described herein. Also described are the use of such compounds and compositions for the treatment of a diverse array of diseases, disorders, and conditions, including cancer- and immune-related disorders that are mediated, at least in part, by the adenosine A2A receptor and/or the adenosine A2B receptor.

  本文描述了可抑制 A2A 和 A2B 腺苷受体中至少一种受体的式 I 化合物，以及含有式 I 化合物的组合物和式 I 化合物的合成方法。 还描述了此类化合物和组合物用于治疗各种疾病、失调和病症的用途，包括至少部分由腺苷 A2A 受体和/或腺苷 A2B 受体介导的癌症和免疫相关疾病。
• WO2018204661A5
  申请人：——

  公开号：WO2018204661A5

  公开（公告）日：2022-08-12
• Quinazoline derivatives
  申请人：SmithKline Beecham Intercredit B.V.

  公开号：EP0322133B1

  公开（公告）日：1991-05-22
• QUINAZOLINE-PYRIDINE DERIVATIVES FOR THE TREATMENT OF CANCER-RELATED DISORDERS
  申请人：Arcus Biosciences, Inc.

  公开号：EP3618829A1

  公开（公告）日：2020-03-11